Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells.
Atacicept (TACI:Fc5) is a homodimeric fusion protein obtained through recombinant DNA technology being developed by Merck Serono SA, under license from ZymoGenetics Inc, for the potential treatment of B-cell diseases. Atacicept is undergoing phase II/III clinical trials for systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, as well as for several B-cell malignancies.
Gatto
Barbara
B
University of Padova, Department of Pharmaceutical Sciences, Padova, Italy. barbara.gatto@unipd.it
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D011993:Recombinant Fusion Proteins; C524618:TACI receptor-IgG Fc fragment fusion protein